Ars Pharmaceuticals Inc (SPRY) Stock Price, Quote & News

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 771 9307

Website: ars-pharma.com

Address:

11682 El Camino Real, Suite 300, San Diego, United States

BigGainTom Apr. 28 at 9:34 PM

$SPRY Garbage... Next up is the huge rug pull.

0 · Reply

ae1213 Apr. 27 at 8:05 PM

$SPRY I love to live in your empty head rent free.

1 · Reply

BigGainTom Apr. 27 at 8:00 PM

$SPRY this company is worse than AE's body odor even after a shower. Putrid.

0 · Reply

ae1213 Apr. 27 at 4:18 PM

$AQST this company has a history of being locked out of market due to competitor exclusivity. Could it happen again with film? I think it is very possible when ACNU is filled along with CNPV voucher $SPRY

2 · Reply

BioPM1989 Apr. 27 at 2:55 PM

$SPRY Big time analysts!

1 · Reply

BigGainTom Apr. 27 at 1:46 PM

$SPRY 43% short interest. A sign of a garbage company.

0 · Reply

buymoremakemore Apr. 26 at 6:47 PM

$DERM $SPRY the audacity of Lupin Pharmaceuticals is insane. Journey and ARS have fair and square patents for Emrosi and Neffy. The judge hopefully rules in Journey and ARS’ favor soon.

2 · Reply

BioPM1989 Apr. 26 at 11:25 AM

$SPRY Comeback soon… Analysts from the Big Apple like it. You know what it takes to make it big in NY? No you don’t…

1 · Reply

ae1213 Apr. 24 at 8:10 PM

$AQST $IOVA $SPRY this novice seemed puzzled. Me, not so much …

1 · Reply

BigGainTom Apr. 24 at 8:02 PM

$AQST $IOVA had huge drops in short interest in latest filing today. $SPRY continues to go up. Now at 42% short interest, crazy .... Ppl think this one will crater.

1 · Reply

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Mar 27, 2026, 8:00 AM EDT - 4 weeks ago

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

Mar 11, 2026, 8:00 AM EDT - 6 weeks ago

ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:30 AM EDT - 7 weeks ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 9, 2026, 6:00 AM EDT - 7 weeks ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

Feb 23, 2026, 8:00 AM EST - 2 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Feb 10, 2026, 8:00 AM EST - 2 months ago

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 2, 2026, 8:00 AM EST - 3 months ago

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to

Jan 21, 2026, 8:00 AM EST - 3 months ago

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

Jan 9, 2026, 12:32 PM EST - 3 months ago

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

Dec 29, 2025, 8:00 AM EST - 4 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

Dec 3, 2025, 2:30 PM EST - 5 months ago

ARS Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 8:00 AM EST - 5 months ago

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 10, 2025, 6:00 AM EST - 6 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

Nov 4, 2025, 8:00 AM EST - 6 months ago

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Nov 3, 2025, 2:23 PM EST - 6 months ago

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Nov 3, 2025, 8:00 AM EST - 6 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

Nov 3, 2025, 7:45 AM EST - 6 months ago

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 8, 2025, 8:00 AM EDT - 7 months ago

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

Sep 29, 2025, 4:05 PM EDT - 7 months ago

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Sep 17, 2025, 9:00 AM EDT - 7 months ago

ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Sep 3, 2025, 3:55 PM EDT - 8 months ago

ARS Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 8 months ago

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 13, 2025, 8:30 AM EDT - 9 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 9 months ago

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

Aug 4, 2025, 8:00 AM EDT - 9 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

Jul 18, 2025, 9:25 AM EDT - 10 months ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Jun 4, 2025, 5:30 PM EDT - 11 months ago

ARS Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:20 PM EDT - 11 months ago

ARS Pharmaceuticals Transcript: 45th Annual William Blair Growth Stock Conference

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

May 7, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 5, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 4:10 PM EST - 1 year ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Mar 3, 2025, 4:35 PM EST - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Feb 20, 2025, 7:02 PM EST - 1 year ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Feb 18, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 12, 2025, 2:40 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Jan 15, 2025, 10:30 AM EST - 1 year ago

ARS Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Dec 19, 2024, 5:25 PM EST - 1 year ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Dec 12, 2024, 2:32 PM EST - 1 year ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Dec 4, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Nov 18, 2024, 2:25 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 1:00 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 6:30 AM EST - 1 year ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 11, 2024, 7:41 AM EST - 1 year ago

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

Nov 11, 2024, 7:00 AM EST - 1 year ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Nov 9, 2024, 5:30 PM EST - 1 year ago

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Nov 4, 2024, 11:00 AM EST - 1 year ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 1 year ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 30, 2024, 11:00 AM EDT - 1 year ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 24, 2024, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 23, 2024, 11:00 AM EDT - 1 year ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Oct 19, 2024, 11:00 AM EDT - 1 year ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 17, 2024, 11:00 AM EDT - 1 year ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

$The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions$

Oct 8, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions

Aug 12, 2024, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Transcript: FDA Announcement

Mar 13, 2024, 10:00 AM EDT - 2 years ago

ARS Pharmaceuticals Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 7, 2024, 1:00 PM EST - 2 years ago

ARS Pharmaceuticals Transcript: Investor Day 2024

Jul 21, 2022, 5:00 PM EDT - 4 years ago

ARS Pharmaceuticals Transcript: M&A Announcement

BigGainTom Apr. 28 at 9:34 PM

$SPRY Garbage... Next up is the huge rug pull.

0 · Reply

ae1213 Apr. 27 at 8:05 PM

$SPRY I love to live in your empty head rent free.

1 · Reply

BigGainTom Apr. 27 at 8:00 PM

$SPRY this company is worse than AE's body odor even after a shower. Putrid.

0 · Reply

ae1213 Apr. 27 at 4:18 PM

2 · Reply

BioPM1989 Apr. 27 at 2:55 PM

$SPRY Big time analysts!

1 · Reply

BigGainTom Apr. 27 at 1:46 PM

$SPRY 43% short interest. A sign of a garbage company.

0 · Reply

buymoremakemore Apr. 26 at 6:47 PM

$DERM $SPRY the audacity of Lupin Pharmaceuticals is insane. Journey and ARS have fair and square patents for Emrosi and Neffy. The judge hopefully rules in Journey and ARS’ favor soon.

2 · Reply

BioPM1989 Apr. 26 at 11:25 AM

$SPRY Comeback soon… Analysts from the Big Apple like it. You know what it takes to make it big in NY? No you don’t…

1 · Reply

ae1213 Apr. 24 at 8:10 PM

$AQST $IOVA $SPRY this novice seemed puzzled. Me, not so much …

1 · Reply

BigGainTom Apr. 24 at 8:02 PM

$AQST $IOVA had huge drops in short interest in latest filing today. $SPRY continues to go up. Now at 42% short interest, crazy .... Ppl think this one will crater.

1 · Reply

PepeDeFraud Apr. 23 at 8:54 PM

@Bullish_Swagger how about $SPRY high SI

0 · Reply

Sdwg Apr. 23 at 3:43 PM

$SPRY back to trading like the turd that it is....

1 · Reply

briank012345 Apr. 23 at 2:16 PM

$SPRY Jesus, we can never hold a gain, can we?

0 · Reply

BlindSquirrel06 Apr. 23 at 6:21 AM

$SPRY volume jump so was soooo 🥵 $SPY $QQQ

0 · Reply

Stone52 Apr. 22 at 11:51 PM

$SPRY 3.8 million shares traded today. Looks to me like a squeeze has started – or something is happening. There’s a reason why someone sold 400,000 shares worth of April 7.5 calls and bought 400,000 shares worth of May 7.5 calls last month.

0 · Reply

OracleofOntario Apr. 22 at 11:26 PM

$SPRY everything going to plan - steadily expanding global markets. If the sales numbers are good at the next ER this one is off to the races.

1 · Reply

ae1213 Apr. 22 at 9:02 PM

$AQST $SPRY @BigGainTom Hey little shmuck, I am still waiting for a thoughtful and deeply researched today’s price action analysis like the one below. What a pathetic “low IQ individual” you are! Your posts and pronouncements are totally irrelevant here. Stop polluting the ciber space and get lost

3 · Reply

OracleofOntario Apr. 22 at 7:43 PM

$SPRY The positive news about Canada was going to get priced in sooner or later

0 · Reply

zenway101 Apr. 22 at 7:24 PM

$SPRY The large share buys are looking particularly interesting... I'm not saying aquisition, but I wouldn't be shocked.

1 · Reply

briank012345 Apr. 22 at 6:37 PM

$SPRY higher than average volume, good price movement. Can we keep it up? 🤔

0 · Reply

ThinkVision Apr. 22 at 3:48 PM

$SPRY earnings in May is right around the corner…. https://ir.ars-pharma.com/news-releases/news-release-details/neffyr-epinephrine-nasal-spray-approved-canada-first-and-only/

0 · Reply

BigGainTom Apr. 22 at 3:15 PM

$SPRY @ae1213 is scurred bro... Let him be... He may have a heart attack.

0 · Reply

Market Cap	823.17M
Revenue (ttm)	84.28M
Net Income (ttm)	-171.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-203.25%
Debt to Equity Ratio	1.47

Volume	1,375,809
Avg Vol	1,443,362
Day's Range	N/A - N/A
Shares Out	99.30M
Stochastic %K	67%
Beta	0.86
Analysts	Strong Sell
Price Target	$25.50